Status:
COMPLETED
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
University of Regensburg
Conditions:
Patients Undergoing Allogeneic Stem Cell Transplantation
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening complication r...
Eligibility Criteria
Inclusion
- Indication for allogeneic stem cell transplantation
- HLA identical donor, related or unrelated, 10/10 match
- Stem cell source: G-SCF mobilized peripheral blood stem cells
- Presence of at least one HLA allele: A0101, A0201, B0702, B0801, B3501, C0702
- Positive EBV serology of the donor
- Positive CMV serology of the donor
- Adequate contraception
Exclusion
- Donor CMV seronegative
- Donor EBV seronegative
- Stem cell source: bone marrow or cord blood
- Alemtuzumab for conditioning
- Sorror Score \>3
- Pregnancy
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02227641
Start Date
October 1 2014
End Date
March 1 2017
Last Update
December 14 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center Augsburg
Augsburg, Germany, 86156
2
Charité University Hospital Berlin
Berlin, Germany, 13353
3
Universitiy Hospital Erlangen
Erlangen, Germany, 91054
4
University of Mainz
Mainz, Germany, 55131